WAVES: Neither HIV Subtype nor Baseline Mutations Affect Efficacy of EVG/COBI/TDF/FTC or ATV/RTV + TDF/FTC in Treatment-Naive, HIV-Infected Women
Conference Capsule - Both regimens demonstrated high genetic barriers to resistance. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 23, 2016 Category: Infectious Diseases Source Type: research
ARIA: Racial Subgroup Analysis Consistent With Overall Efficacy and Safety Findings for Dolutegravir/Abacavir/Lamivudine in Treatment-Naive Women
Conference Capsule - Low rates of psychiatric adverse events in DTG/ABC/3TC and ATV/RTV plus TDF/FTC treatment arms. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 17, 2016 Category: Infectious Diseases Source Type: research
DOMONO: Dolutegravir Maintenance Monotherapy as Effective as Continued Triple-Therapy ART for Virologically Suppressed, HIV-Infected Patients
Conference Capsule - Four of 85 patients completing 24 weeks of dolutegravir treatment experienced virologic failure. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 17, 2016 Category: Infectious Diseases Source Type: research
Study 311-1089: 96-Week Follow-up Confirms Noninferiority and Renal/Bone Safety of Switching From FTC/TDF to FTC/TAF in Virologically Suppressed Patients Receiving a Third Agent
Conference Capsule - Efficacy and safety outcomes were independent of third agent and at Week 48 were consistent in patients 50 years of age or older. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 17, 2016 Category: Infectious Diseases Source Type: research
GESIDA-8104-DUAL: Virologic Efficacy of Switch to DRV-Based Dual ART Noninferior to Continuing DRV-Based Triple ART in Virologically Suppressed Patients
Conference Capsule - After 48 weeks, switch to DRV/RTV plus 3TC from DRV/RTV plus TDF/FTC or ABC/3TC was well tolerated and associated with maintenance of virologic suppression without emergent resistance. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 16, 2016 Category: Infectious Diseases Source Type: research
AI438011: GSK3684934 1200 mg QD Dose Effective and Safe at 96 Weeks
Conference Capsule - Similar virologic efficacy observed across disease and demographic subgroups. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 16, 2016 Category: Infectious Diseases Source Type: research
Fall 2016 HIV Update
Slideset - In this downloadable slideset, Anton L. Pozniak, MD, FRCP, and Joseph J. Eron, MD, review key studies presented at the 2016 Glasgow HIV and IDWeek meetings. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 15, 2016 Category: Infectious Diseases Source Type: research
ART Under Pressure: Comparing Regimens in Challenging Clinical Scenarios
Audio - Listen to downloadable audio from a series of live Webinars in which Daniel R. Kuritzkes, MD, reviews key factors governing selection of antiretroviral therapy in patients with complex clinical needs and discusses new data from HIV Glasgow 2016. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 14, 2016 Category: Infectious Diseases Source Type: research
ART Under Pressure: Comparing Regimens in Challenging Scenarios
Slideset - This downloadable slideset summarizes optimal evidence-based antiretroviral therapy management strategies for a series of challenging clinical cases and is based on a satellite symposium presented at HIV Glasgow 2016. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 11, 2016 Category: Infectious Diseases Source Type: research
Studies 1216 and 1160: Switching to RPV/FTC/TAF Noninferior to Continued RPV/FTC/TDF or EFV/FTC/TDF in Virologically Suppressed Patients at Week 48
Conference Capsule - Switch to RPV/FTC/TAF from NNRTI/FTC/TDF-containing regimen associated with significant improvements in markers of renal and bone safety. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 10, 2016 Category: Infectious Diseases Source Type: research
Psychiatric Adverse Events Are Rare and Low Grade in Treatment-Naive HIV-Positive Patients Treated With Dolutegravir in Clinical Trials
Conference Capsule - Insomnia was the most common dolutegravir-related psychiatric adverse event in all 4 examined trials. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 10, 2016 Category: Infectious Diseases Source Type: research
Treatment-Experienced Patients on Stable DRV-Based Therapy With Multiclass Resistance Maintain HIV-1 RNA Suppression Following Switch to EVG/COBI/TAF/FTC + DRV vs Continuing Baseline ART Regardless of Study Entry DRV Dose or Baseline GSS
Conference Capsule - Previous DRV dose and baseline genotypic susceptibility score did not negatively affect the efficacy of switching from DRV-containing ART to EVG/COBI/TAF/FTC plus DRV. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 8, 2016 Category: Infectious Diseases Source Type: research
Evaluation of Neuropsychiatric Events With INSTIs in Real-World German Cohort
Conference Capsule - Discontinuation for neuropsychiatric events more common for dolutegravir and comprised primarily sleep disturbances and insomnia; women, older adults, and patients initiating concurrent abacavir at increased risk. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 8, 2016 Category: Infectious Diseases Source Type: research
Choosing Among Current Antiretroviral Regimens: The Relevance of Drug –Drug Interactions and Barrier to Resistance
Audio - Listen to downloadable audio from a series of live Webinars in which J ürgen K. Rockstroh, MD, provides expert insight into the influence of drug–drug interactions and differing antiretroviral genetic barriers to resistance on selection of antiretroviral therapy and addresses audience questions on this subject. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 4, 2016 Category: Infectious Diseases Source Type: research
Choosing Among Current Antiretroviral Regimens: The Relevance of Drug –Drug Interactions and Barrier to Resistance
Slideset - In this downloadable slideset, J ürgen K. Rockstroh, MD, reviews how selection of antiretroviral therapy is influenced by drug–drug interactions and differing antiretroviral genetic barriers to resistance. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - November 4, 2016 Category: Infectious Diseases Source Type: research
